Kate I Patterson

Summary

Affiliation: Garvan Institute of Medical Research
Country: Australia

Publications

  1. ncbi Dual-specificity phosphatases: critical regulators with diverse cellular targets
    Kate I Patterson
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst 2010, Sydney, NSW, Australia
    Biochem J 418:475-89. 2009
  2. ncbi DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs
    Kate I Patterson
    Garvan Institute of Medical Research, Darlinghurst, NSW, 2010 Australia
    Biochim Biophys Acta 1803:1003-12. 2010
  3. ncbi Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers
    Brian S Gloss
    Cancer Research Program, The Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, New South Wales 2010, Australia
    Cancer Lett 318:76-85. 2012

Collaborators

Detail Information

Publications3

  1. ncbi Dual-specificity phosphatases: critical regulators with diverse cellular targets
    Kate I Patterson
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst 2010, Sydney, NSW, Australia
    Biochem J 418:475-89. 2009
    ..The present review provides an overview of the DUSP family before focusing on atypical DUSPs, emerging as a group of proteins with vastly diverse substrate specificity and function...
  2. ncbi DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs
    Kate I Patterson
    Garvan Institute of Medical Research, Darlinghurst, NSW, 2010 Australia
    Biochim Biophys Acta 1803:1003-12. 2010
    ..In addition, they indicate that DUSP26 may function as a tumour suppressor in particular cancers...
  3. ncbi Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers
    Brian S Gloss
    Cancer Research Program, The Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, New South Wales 2010, Australia
    Cancer Lett 318:76-85. 2012
    ..05). We propose that this potential biomarker panel holds great promise as a diagnostic test for high-grade (Type II) serous ovarian cancer...